{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:38Z","timestamp":1791918938021,"version":"4.3.4"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"DOI":"10.1007\/s11481-025-10206-5","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:13:35Z","timestamp":1745658815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Unmasking a Paradox: Roles of the PD-1\/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation"],"prefix":"10.1007","volume":"20","author":[{"given":"Ali","family":"Moadab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khorramdelazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Taha Akbari","family":"Javar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad saber Mohammadian","family":"Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Mirzaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Askari","family":"Yazdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"10206_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41593-024-01847-5","volume":"28","author":"MA Abellanas","year":"2025","unstructured":"Abellanas MA, Purnapatre M, Burgaletto C et al (2025) Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer\u2019s disease. Nat Neurosci 28:436\u2013445. https:\/\/doi.org\/10.1038\/s41593-024-01847-5","journal-title":"Nat Neurosci"},{"issue":"12","key":"10206_CR2","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/jnr.24075","volume":"95","author":"C Acosta","year":"2017","unstructured":"Acosta C, Anderson HD, Anderson CM (2017) Astrocyte dysfunction in Alzheimer disease. J Neurosci Res 95(12):2430\u20132447","journal-title":"J Neurosci Res"},{"key":"10206_CR3","doi-asserted-by":"publisher","first-page":"1347987","DOI":"10.3389\/fnagi.2024.1347987","volume":"16","author":"A Adamu","year":"2024","unstructured":"Adamu A et al (2024) The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Frontiers in Aging Neuroscience 16:1347987","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"25","key":"10206_CR4","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.2174\/138161210793176572","volume":"16","author":"P Agostinho","year":"2010","unstructured":"Agostinho P, Cunha RA, Oliveira C (2010) Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer\u2019s disease. Curr Pharma Des 16(25):2766\u20132778","journal-title":"Curr Pharma Des"},{"issue":"10","key":"10206_CR5","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3390\/cells10102555","volume":"10","author":"M Andoh","year":"2021","unstructured":"Andoh M, Koyama R (2021) Comparative review of microglia and monocytes in CNS phagocytosis. Cells 10(10):2555","journal-title":"Cells"},{"issue":"4","key":"10206_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14728222.2020.1738391","volume":"24","author":"S Anwar","year":"2020","unstructured":"Anwar S, Rivest S (2020) Alzheimer\u2019s disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation. Expert Opin Ther Targets 24(4):331\u2013344","journal-title":"Expert Opin Ther Targets"},{"key":"10206_CR7","doi-asserted-by":"publisher","first-page":"112328","DOI":"10.1016\/j.intimp.2024.112328","volume":"135","author":"R Arfaei","year":"2024","unstructured":"Arfaei R et al (2024) Decoding the role of the CCL2\/CCR2 axis in Alzheimer\u2019s disease and innovating therapeutic approaches: Keeping All options open. Int Immunopharmacol 135:112328","journal-title":"Int Immunopharmacol"},{"key":"10206_CR8","doi-asserted-by":"publisher","first-page":"148589","DOI":"10.1016\/j.brainres.2023.148589","volume":"1821","author":"MO Asamu","year":"2023","unstructured":"Asamu MO et al (2023) Alzheimer\u2019s disease: The role of T lymphocytes in neuroinflammation and neurodegeneration. Brain Res 1821:148589","journal-title":"Brain Res"},{"key":"10206_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jns.2017.03.031","volume":"376","author":"E Bagyinszky","year":"2017","unstructured":"Bagyinszky E et al (2017) Role of inflammatory molecules in the Alzheimer\u2019s disease progression and diagnosis. J Neurol Sci 376:242\u2013254","journal-title":"J Neurol Sci"},{"issue":"66","key":"10206_CR10","doi-asserted-by":"publisher","first-page":"110693","DOI":"10.18632\/oncotarget.22690","volume":"8","author":"J Bai","year":"2017","unstructured":"Bai J et al (2017) Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade. Oncotarget 8(66):110693","journal-title":"Oncotarget"},{"key":"10206_CR11","doi-asserted-by":"crossref","unstructured":"Barb\u00e9-Tuana F et al (2020) The interplay between immunosenescence and age-related diseases. In Seminars in immunopathology. Springer.","DOI":"10.1007\/s00281-020-00806-z"},{"key":"10206_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fnagi.2020.00135","volume":"12","author":"K Baruch","year":"2020","unstructured":"Baruch K, Yoles E (2020) Commentary: chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front Aging Neurosci 12:135","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10206_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nm.4022","volume":"22","author":"K Baruch","year":"2016","unstructured":"Baruch K et al (2016) PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease. Nat Med 22(2):135\u2013137","journal-title":"Nat Med"},{"issue":"5","key":"10206_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/mp.2008.96","volume":"14","author":"K Bates","year":"2009","unstructured":"Bates K et al (2009) Clearance mechanisms of Alzheimer\u2019s amyloid-\u03b2 peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14(5):469\u2013486","journal-title":"Mol Psychiatry"},{"key":"10206_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s11481-020-09908-9","volume":"15","author":"JE Baulch","year":"2020","unstructured":"Baulch JE et al (2020) Immune and inflammatory determinants underlying Alzheimer\u2019s disease pathology. J Neuroimmune Pharmacol 15:852\u2013862","journal-title":"J Neuroimmune Pharmacol"},{"key":"10206_CR16","unstructured":"Bjursten S (2023) Checkpoint inhibitor-induced adverse events in the CNS-T-cell characteristics and biomarkers"},{"key":"10206_CR17","doi-asserted-by":"crossref","unstructured":"Bjursten S et al (2024) Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor\u2013induced CNS inflammation. EBioMedicine 100","DOI":"10.1016\/j.ebiom.2023.104955"},{"key":"10206_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54:307\u2013314","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10206_CR19","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1161\/STROKEAHA.115.010592","volume":"46","author":"S Bodhankar","year":"2015","unstructured":"Bodhankar S et al (2015) PD-L1 monoclonal antibody treats ischemic stroke by controlling central nervous system inflammation. Stroke 46(10):2926\u20132934","journal-title":"Stroke"},{"issue":"1","key":"10206_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-024-02757-3","volume":"148","author":"P BotellaLucena","year":"2024","unstructured":"BotellaLucena P, Heneka MT (2024) Inflammatory aspects of Alzheimer\u2019s disease. Acta Neuropathol 148(1):1\u201321","journal-title":"Acta Neuropathol"},{"key":"10206_CR21","first-page":"813","volume-title":"Encyclopedia of molecular pharmacology","author":"A Brioli","year":"2022","unstructured":"Brioli A, Hochhaus A (2022) Immune checkpoint blockade. Encyclopedia of molecular pharmacology. Springer, pp 813\u2013820"},{"key":"10206_CR22","doi-asserted-by":"crossref","unstructured":"Cai J et al (2019) The role of PD-1\/PD-L1 axis in treg development and function: implications for cancer immunotherapy. OncoTargets Therapy 8437\u20138445","DOI":"10.2147\/OTT.S221340"},{"issue":"3","key":"10206_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.nbd.2009.10.006","volume":"37","author":"B Cameron","year":"2010","unstructured":"Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer\u2019s disease. Neurobiol Dis 37(3):503\u2013509","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10206_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2174\/1567205013666160620111408","volume":"14","author":"AM Catafau","year":"2017","unstructured":"Catafau AM, Bullich S (2017) Non-amyloid PET imaging biomarkers for neurodegeneration: focus on tau, alpha-synuclein and neuroinflammation. Curr Alzheimer Res 14(2):169\u2013177","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"10206_CR25","first-page":"277","volume":"7","author":"MT Cencioni","year":"2020","unstructured":"Cencioni MT (2020) The immune regulation of PD-1\/PDL-1 axis, a potential biomarker in multiple sclerosis. Neuroimmunol Neuroinflamm 7(3):277\u2013290","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"10206_CR26","doi-asserted-by":"publisher","first-page":"703972","DOI":"10.3389\/fimmu.2021.703972","volume":"12","author":"MD Ch\u00e1vez","year":"2021","unstructured":"Ch\u00e1vez MD, Tse HM (2021) Targeting mitochondrial-derived reactive oxygen species in T cell-mediated autoimmune diseases. Front Immunol 12:703972","journal-title":"Front Immunol"},{"issue":"4","key":"10206_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15616\/BSL.2018.24.4.305","volume":"24","author":"G-E Choi","year":"2018","unstructured":"Choi G-E (2018) Crosstalk Signaling between IFN-\u03b3 and TGF-\u03b2 in microglia restores the defective \u03b2-amyloid clearance pathway in aging mice with alzheimer\u2019s disease. Biomed Sci Lett 24(4):305\u2013310","journal-title":"Biomed Sci Lett"},{"issue":"12","key":"10206_CR28","doi-asserted-by":"publisher","first-page":"e13511","DOI":"10.1111\/acel.13511","volume":"20","author":"L Dai","year":"2021","unstructured":"Dai L, Shen Y (2021) Insights into T-cell dysfunction in Alzheimer\u2019s disease. Aging Cell 20(12):e13511","journal-title":"Aging Cell"},{"key":"10206_CR29","doi-asserted-by":"crossref","unstructured":"Dalakas MC (2019) Autoimmune peripheral neuropathies, in Clinical immunology. Elsevier. 903\u2013915. e1.","DOI":"10.1016\/B978-0-7020-6896-6.00067-3"},{"key":"10206_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP et al (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22:1\u201311","journal-title":"Curr Oncol Rep"},{"issue":"30","key":"10206_CR31","doi-asserted-by":"publisher","first-page":"27620","DOI":"10.1074\/jbc.M303199200","volume":"278","author":"M Delgado","year":"2003","unstructured":"Delgado M (2003) Inhibition of interferon (IFN) \u03b3-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J Biol Chem 278(30):27620\u201327629","journal-title":"J Biol Chem"},{"issue":"18","key":"10206_CR32","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.3390\/cancers13184509","volume":"13","author":"D Delmas","year":"2021","unstructured":"Delmas D, Hermetet F, Aires V (2021) PD-1\/PD-L1 checkpoints and resveratrol: a controversial new way for a therapeutic strategy. Cancers 13(18):4509","journal-title":"Cancers"},{"issue":"8","key":"10206_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2174\/1567205014666170317113606","volume":"14","author":"C Domingues","year":"2017","unstructured":"Domingues C, da Cruz e Silva ABO, Henriques A (2017) Impact of cytokines and chemokines on Alzheimer\u2019s disease neuropathological hallmarks. Curr Alzheimer Res 14(8):870\u2013882","journal-title":"Curr Alzheimer Res"},{"issue":"17","key":"10206_CR34","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.3390\/jcm13175057","volume":"13","author":"J Doroszkiewicz","year":"2024","unstructured":"Doroszkiewicz J et al (2024) Metabolic and immune system dysregulation: Unraveling the connections between alzheimer\u2019s disease, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. J Clin Med 13(17):5057","journal-title":"J Clin Med"},{"key":"10206_CR35","doi-asserted-by":"crossref","unstructured":"Fani Maleki A, Rivest S (2019)\u00a0Innate immune cells: monocytes, monocyte-derived macrophages and microglia as therapeutic targets for Alzheimer\u2019s disease and multiple sclerosis. Front Cell Neurosci 13:355","DOI":"10.3389\/fncel.2019.00355"},{"issue":"2","key":"10206_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/braincomms\/fcaa112","volume":"2","author":"A Faridar","year":"2020","unstructured":"Faridar A et al (2020) Restoring regulatory T-cell dysfunction in Alzheimer\u2019s disease through ex vivo expansion. Brain Commun 2(2):112","journal-title":"Brain Commun"},{"key":"10206_CR37","doi-asserted-by":"crossref","unstructured":"Feghali J, Jackson CM (2024) Therapeutic implications for the PD-1 axis in cerebrovascular injury. Neurotherapeutics e00459","DOI":"10.1016\/j.neurot.2024.e00459"},{"key":"10206_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601\u2013609","journal-title":"J Neurooncol"},{"issue":"3","key":"10206_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/JAD-2005-7304","volume":"7","author":"M Fiala","year":"2005","unstructured":"Fiala M et al (2005) Ineffective phagocytosis of amyloid-\u03b2 by macrophages of Alzheimer\u2019s disease patients. J Alzheimers Dis 7(3):221\u2013232","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10206_CR40","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s00262-021-03130-z","volume":"71","author":"A Filippone","year":"2022","unstructured":"Filippone A et al (2022) PD1\/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. Cancer Immunol Immunother 71(9):2067\u20132075","journal-title":"Cancer Immunol Immunother"},{"key":"10206_CR41","doi-asserted-by":"publisher","first-page":"1305933","DOI":"10.3389\/fimmu.2023.1305933","volume":"14","author":"L Fornari Laurindo","year":"2024","unstructured":"Fornari Laurindo L et al (2024) Immunological dimensions of neuroinflammation and microglial activation: Exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression. Front Immunol 14:1305933","journal-title":"Front Immunol"},{"issue":"4","key":"10206_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hon.2375","volume":"35","author":"M Four","year":"2017","unstructured":"Four M et al (2017) PD 1 and PDL 1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD 1 predicts poor survival. Hematol Oncol 35(4):487\u2013496","journal-title":"Hematol Oncol"},{"issue":"1","key":"10206_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12974-022-02398-x","volume":"19","author":"X Gao","year":"2022","unstructured":"Gao X et al (2022) PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury. J Neuroinflammation 19(1):43","journal-title":"J Neuroinflammation"},{"issue":"13","key":"10206_CR44","doi-asserted-by":"publisher","first-page":"10905","DOI":"10.3390\/ijms241310905","volume":"24","author":"M Ghareghani","year":"2023","unstructured":"Ghareghani M, Rivest S (2023) The synergistic potential of combining PD-1\/PD-L1 immune checkpoint inhibitors with NOD2 Agonists in Alzheimer\u2019s disease treatment. Int J Mol Sci 24(13):10905","journal-title":"Int J Mol Sci"},{"key":"10206_CR45","doi-asserted-by":"publisher","first-page":"109131","DOI":"10.1016\/j.yebeh.2023.109131","volume":"140","author":"G Giovannini","year":"2023","unstructured":"Giovannini G et al (2023) Neuro-glial degeneration in Status Epilepticus: Exploring the role of serum levels of Neurofilament light chains and S100B as prognostic biomarkers for short-term functional outcome. Epilepsy Behav 140:109131","journal-title":"Epilepsy Behav"},{"key":"10206_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mehy.2019.01.007","volume":"123","author":"ON Gofrit","year":"2019","unstructured":"Gofrit ON et al (2019) Can immunization with Bacillus Calmette-Gu\u00e9rin (BCG) protect against Alzheimer\u2019s disease? Med Hypotheses 123:95\u201397","journal-title":"Med Hypotheses"},{"issue":"10","key":"10206_CR47","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/cbin.11846","volume":"46","author":"A Gowhari Shabgah","year":"2022","unstructured":"Gowhari Shabgah A et al (2022) A comprehensive review of chemokine CXC17 (VCC1) in cancer, infection, and inflammation. Cell Biol Int 46(10):1557\u20131570","journal-title":"Cell Biol Int"},{"key":"10206_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000437178","volume":"42","author":"JB Haanen","year":"2015","unstructured":"Haanen JB, Robert C (2015) Immune Checkpoint Inhibitors. Immuno-Oncol 42:55\u201366","journal-title":"Immuno-Oncol"},{"issue":"6","key":"10206_CR49","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1523\/JNEUROSCI.3516-14.2015","volume":"35","author":"LB Haim","year":"2015","unstructured":"Haim LB et al (2015) The JAK\/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer\u2019s and Huntington\u2019s diseases. J Neurosci 35(6):2817\u20132829","journal-title":"J Neurosci"},{"key":"10206_CR50","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han SJ et al (2016) Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol 130:543\u2013552","journal-title":"J Neurooncol"},{"issue":"4","key":"10206_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19(4):479\u2013488","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10206_CR52","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1073\/pnas.0805453106","volume":"106","author":"CA Hawkes","year":"2009","unstructured":"Hawkes CA, McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of \u03b2-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci 106(4):1261\u20131266","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10206_CR53","first-page":"153","volume":"5","author":"F He","year":"2013","unstructured":"He F, Balling R (2013) The role of regulatory T cells in neurodegenerative diseases. Wiley Interdiscip Rev: Syst Biol Med 5(2):153\u2013180","journal-title":"Wiley Interdiscip Rev: Syst Biol Med"},{"issue":"6","key":"10206_CR54","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.4049\/jimmunol.175.6.3637","volume":"175","author":"X Hu","year":"2005","unstructured":"Hu X et al (2005) IFN-\u03b3-primed macrophages exhibit increased CCR2-dependent migration and altered IFN-\u03b3 responses mediated by Stat1. J Immunol 175(6):3637\u20133647","journal-title":"J Immunol"},{"key":"10206_CR55","unstructured":"Huang S et al (n.d) PD-1\/PD-L1 Inhibitors for Alzheimer\u2019s Pathology: A Literature."},{"key":"10206_CR56","doi-asserted-by":"publisher","first-page":"1197364","DOI":"10.3389\/fimmu.2023.1197364","volume":"14","author":"B Ibis","year":"2023","unstructured":"Ibis B et al (2023) Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol 14:1197364","journal-title":"Front Immunol"},{"key":"10206_CR57","doi-asserted-by":"publisher","first-page":"104778","DOI":"10.1016\/j.cellimm.2023.104778","volume":"393","author":"A Jafarzadeh","year":"2023","unstructured":"Jafarzadeh A et al (2023) Differential roles of regulatory T cells in Alzheimer\u2019s disease. Cell Immunol 393:104778","journal-title":"Cell Immunol"},{"key":"10206_CR58","doi-asserted-by":"publisher","first-page":"906251","DOI":"10.3389\/fonc.2022.906251","volume":"12","author":"M Jiang","year":"2022","unstructured":"Jiang M et al (2022) Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol 12:906251","journal-title":"Front Oncol"},{"issue":"10","key":"10206_CR59","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC et al (2017) Neurological complications associated with anti\u2013programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222","journal-title":"JAMA Neurol"},{"issue":"1","key":"10206_CR60","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26(1):677\u2013704","journal-title":"Annu Rev Immunol"},{"key":"10206_CR61","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bbi.2023.12.007","volume":"116","author":"JE Kim","year":"2024","unstructured":"Kim JE et al (2024) Soluble PD-L1 reprograms blood monocytes to prevent cerebral edema and facilitate recovery after ischemic stroke. Brain Behav Immun 116:160\u2013174","journal-title":"Brain Behav Immun"},{"key":"10206_CR62","doi-asserted-by":"publisher","first-page":"861956","DOI":"10.3389\/fnagi.2022.861956","volume":"14","author":"BY Klein","year":"2022","unstructured":"Klein BY et al (2022) Bacillus Calmette-Gu\u00e9rin in immuno-regulation of alzheimer\u2019s disease. Front Aging Neurosci 14:861956","journal-title":"Front Aging Neurosci"},{"issue":"44","key":"10206_CR63","doi-asserted-by":"publisher","first-page":"9838","DOI":"10.1523\/JNEUROSCI.2557-04.2004","volume":"24","author":"J Koenigsknecht","year":"2004","unstructured":"Koenigsknecht J, Landreth G (2004) Microglial phagocytosis of fibrillar \u03b2-amyloid through a \u03b21 integrin-dependent mechanism. J Neurosci 24(44):9838\u20139846","journal-title":"J Neurosci"},{"issue":"1","key":"10206_CR64","first-page":"9999146","volume":"2021","author":"R K\u00f6lliker-Frers","year":"2021","unstructured":"K\u00f6lliker-Frers R et al (2021) Neuroinflammation: an integrating overview of reactive-Neuroimmune cell interactions in health and disease. Mediators Inflamm 2021(1):9999146","journal-title":"Mediators Inflamm"},{"key":"10206_CR65","doi-asserted-by":"publisher","first-page":"638873","DOI":"10.3389\/fonc.2021.638873","volume":"11","author":"Y Kong","year":"2021","unstructured":"Kong Y et al (2021) Optimizing the treatment schedule of radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy in metastatic cancers. Front Oncol 11:638873","journal-title":"Front Oncol"},{"issue":"7","key":"10206_CR66","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3390\/ijerph8072980","volume":"8","author":"AD Kraft","year":"2011","unstructured":"Kraft AD, Harry GJ (2011) Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 8(7):2980\u20133018","journal-title":"Int J Environ Res Public Health"},{"issue":"65","key":"10206_CR67","doi-asserted-by":"publisher","first-page":"eabf4034","DOI":"10.1126\/sciimmunol.abf4034","volume":"6","author":"JR Kuchroo","year":"2021","unstructured":"Kuchroo JR et al (2021) The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol 6(65):eabf4034","journal-title":"Sci Immunol"},{"key":"10206_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41541-018-0062-8","volume":"3","author":"W Kuhtreiber","year":"2018","unstructured":"Kuhtreiber W (2018) Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. Npj Vaccines 3:23","journal-title":"Npj Vaccines"},{"issue":"24","key":"10206_CR69","doi-asserted-by":"publisher","first-page":"e108662","DOI":"10.15252\/embj.2021108662","volume":"40","author":"MP Kummer","year":"2021","unstructured":"Kummer MP et al (2021) Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer\u2019s disease pathology. EMBO J 40(24):e108662","journal-title":"EMBO J"},{"issue":"2","key":"10206_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/imt-2017-0120","volume":"10","author":"N Kuol","year":"2018","unstructured":"Kuol N et al (2018) PD-1\/PD-L1 in disease. Immunotherapy 10(2):149\u2013160","journal-title":"Immunotherapy"},{"issue":"7","key":"10206_CR71","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers14071710","volume":"14","author":"M Kuske","year":"2022","unstructured":"Kuske M et al (2022) Immunomodulatory properties of immune checkpoint inhibitors\u2014more than boosting T-cell responses? Cancers 14(7):1710","journal-title":"Cancers"},{"issue":"6","key":"10206_CR72","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1586\/1744666X.2014.909286","volume":"10","author":"M Lagranderie","year":"2014","unstructured":"Lagranderie M, Guyonvarc\u2019h P-M (2014) The interplay between bacillus Calmette-Guerin and Treg cells and its role to prevent or cure inflammatory diseases. Expert Rev Clin Immunol 10(6):741\u2013745","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10206_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2217\/fnl.12.6","volume":"7","author":"AY Lai","year":"2012","unstructured":"Lai AY, McLaurin J (2012) Clearance of amyloid-\u03b2 peptides by microglia and macrophages: the issue of what, when and where. Future Neurol 7(2):165\u2013176","journal-title":"Future Neurol"},{"issue":"1","key":"10206_CR74","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12576-024-00933-4","volume":"74","author":"NN Lasheen","year":"2024","unstructured":"Lasheen NN et al (2024) Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders. J Physiol Sci 74(1):46","journal-title":"J Physiol Sci"},{"issue":"7","key":"10206_CR75","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2326-6066.CIR-22-0953","volume":"11","author":"EY Lemma","year":"2023","unstructured":"Lemma EY et al (2023) Regulation of PD-L1 Trafficking from Synthesis to Degradation. Cancer Immunol Res 11(7):866\u2013874","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10206_CR76","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"X Li","year":"2019","unstructured":"Li X et al (2019) Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol 16(7):425\u2013441","journal-title":"Nat Rev Clin Oncol"},{"key":"10206_CR77","doi-asserted-by":"publisher","first-page":"716747","DOI":"10.3389\/fncel.2021.716747","volume":"15","author":"H Li","year":"2021","unstructured":"Li H et al (2021) PD-1\/PD-L1 axis as a potential therapeutic target for multiple sclerosis: AT cell perspective. Front Cell Neurosci 15:716747","journal-title":"Front Cell Neurosci"},{"key":"10206_CR78","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fnagi.2019.00377","volume":"11","author":"Y Lin","year":"2020","unstructured":"Lin Y et al (2020) Chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front Aging Neurosci 11:377","journal-title":"Front Aging Neurosci"},{"key":"10206_CR79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fnagi.2020.00205","volume":"12","author":"Y Lin","year":"2020","unstructured":"Lin Y et al (2020) Response: Commentary: Chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front Aging Neurosci 12:205","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10206_CR80","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1038\/s41467-023-40982-8","volume":"14","author":"M Linnerbauer","year":"2023","unstructured":"Linnerbauer M et al (2023) PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation. Nat Commun 14(1):5555","journal-title":"Nat Commun"},{"issue":"21","key":"10206_CR81","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.3390\/ijms20215347","volume":"20","author":"J Litak","year":"2019","unstructured":"Litak J et al (2019) PD-L1\/PD-1 axis in glioblastoma multiforme. Int J Mol Sci 20(21):5347","journal-title":"Int J Mol Sci"},{"key":"10206_CR82","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cytogfr.2022.07.003","volume":"67","author":"J Lu","year":"2022","unstructured":"Lu J et al (2022) Revisiting PD-1\/PD-L pathway in T and B cell response: Beyond immunosuppression. Cytokine Growth Factor Rev 67:58\u201365","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10206_CR83","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neurobiolaging.2014.08.008","volume":"36","author":"G Lueg","year":"2015","unstructured":"Lueg G et al (2015) Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer\u2019s disease. Neurobiol Aging 36(1):81\u201389","journal-title":"Neurobiol Aging"},{"key":"10206_CR84","doi-asserted-by":"publisher","first-page":"652111","DOI":"10.3389\/fncel.2021.652111","volume":"15","author":"J Lutshumba","year":"2021","unstructured":"Lutshumba J, Nikolajczyk BS, Bachstetter AD (2021) Dysregulation of systemic immunity in aging and dementia. Front Cell Neurosci 15:652111","journal-title":"Front Cell Neurosci"},{"key":"10206_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-021-02308-7","volume":"18","author":"J Machhi","year":"2021","unstructured":"Machhi J et al (2021) CD4+ effector T cells accelerate Alzheimer\u2019s disease in mice. J Neuroinflammation 18:1\u201323","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10206_CR86","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/ijms19030831","volume":"19","author":"S Mammana","year":"2018","unstructured":"Mammana S et al (2018) The role of macrophages in neuroinflammatory and neurodegenerative pathways of Alzheimer\u2019s disease, amyotrophic lateral sclerosis, and multiple sclerosis: pathogenetic cellular effectors and potential therapeutic targets. Int J Mol Sci 19(3):831","journal-title":"Int J Mol Sci"},{"key":"10206_CR87","doi-asserted-by":"crossref","unstructured":"Mandrekar-Colucci S, Landreth GE (2010) Microglia and inflammation in Alzheimer's disease. CNS Neurol Disorders-Drug Targets (Formerly Curr Drug Targets-CNS Neurol Disorders) 9(2): 156\u2013167.","DOI":"10.2174\/187152710791012071"},{"key":"10206_CR88","doi-asserted-by":"publisher","first-page":"877936","DOI":"10.3389\/fneur.2022.877936","volume":"13","author":"S Manenti","year":"2022","unstructured":"Manenti S et al (2022) PD-1\/PD-L axis in neuroinflammation: new insights. Front Neurol 13:877936","journal-title":"Front Neurol"},{"issue":"12","key":"10206_CR89","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2174\/1381612826666200114105515","volume":"26","author":"PR Manzine","year":"2020","unstructured":"Manzine PR et al (2020) Blood-based biomarkers of Alzheimer\u2019s disease: the long and winding road. Curr Pharm Des 26(12):1300\u20131315","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10206_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/acel.12522","volume":"16","author":"E Martin","year":"2017","unstructured":"Martin E et al (2017) Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer\u2019s disease models: Effects of aging and amyloid pathology. Aging Cell 16(1):27\u201338","journal-title":"Aging Cell"},{"key":"10206_CR91","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2019.04.035","volume":"117","author":"L Mazzarella","year":"2019","unstructured":"Mazzarella L et al (2019) The evolving landscape of \u2018next-generation\u2019immune checkpoint inhibitors: A review. Eur J Cancer 117:14\u201331","journal-title":"Eur J Cancer"},{"key":"10206_CR92","doi-asserted-by":"crossref","unstructured":"Mehrabadi S (2024) The Therapeutic Potential of Targeting the Pd-L1\/Pd-1 Immune Checkpoint Pathway in Alzheimer's Disease. Current Aging Science, 2024.","DOI":"10.2174\/0118746098342537241121042621"},{"issue":"1\u20132","key":"10206_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","volume":"210","author":"A Michelucci","year":"2009","unstructured":"Michelucci A et al (2009) Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-\u03b2. J Neuroimmunol 210(1\u20132):3\u201312","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10206_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11481-011-9287-2","volume":"7","author":"SL Montgomery","year":"2012","unstructured":"Montgomery SL, Bowers WJ (2012) Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol 7(1):42\u201359","journal-title":"J Neuroimmune Pharmacol"},{"issue":"16","key":"10206_CR95","doi-asserted-by":"publisher","first-page":"9305","DOI":"10.3390\/ijms23169305","volume":"23","author":"X Morat\u00f3","year":"2022","unstructured":"Morat\u00f3 X et al (2022) Symptomatic and disease-modifying therapy pipeline for Alzheimer\u2019s disease: Towards a personalized polypharmacology patient-centered approach. Int J Mol Sci 23(16):9305","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10206_CR96","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/neuonc\/noad198","volume":"26","author":"L M\u00fcller-Jensen","year":"2024","unstructured":"M\u00fcller-Jensen L et al (2024) Immune signatures of checkpoint inhibitor-induced autoimmunity\u2014A focus on neurotoxicity. Neuro Oncol 26(2):279\u2013294","journal-title":"Neuro Oncol"},{"issue":"5","key":"10206_CR97","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/cancers15051615","volume":"15","author":"JS Myers","year":"2023","unstructured":"Myers JS et al (2023) First-line immunotherapy with check-point inhibitors: prospective assessment of cognitive function. Cancers 15(5):1615","journal-title":"Cancers"},{"key":"10206_CR98","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bbi.2018.08.006","volume":"73","author":"J Obst","year":"2018","unstructured":"Obst J et al (2018) PD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration. Brain Behav Immun 73:708\u2013716","journal-title":"Brain Behav Immun"},{"issue":"5","key":"10206_CR99","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines9050524","volume":"9","author":"IG Onyango","year":"2021","unstructured":"Onyango IG et al (2021) Neuroinflammation in alzheimer\u2019s disease. Biomedicines 9(5):524","journal-title":"Biomedicines"},{"key":"10206_CR100","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fimmu.2015.00539","volume":"6","author":"PA Ottum","year":"2015","unstructured":"Ottum PA et al (2015) Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front Immunol 6:539","journal-title":"Front Immunol"},{"key":"10206_CR101","unstructured":"Park T et al (2024) Intracortical injection of immune checkpoint inhibitor promotes monocyte\/macrophage infiltration and restores microglial function and neuronal activity in an AD mouse model. bioRxiv, 2024.09. 13.612389."},{"key":"10206_CR102","doi-asserted-by":"publisher","first-page":"110865","DOI":"10.1016\/j.mehy.2022.110865","volume":"164","author":"SP Patil","year":"2022","unstructured":"Patil SP et al (2022) Alzheimer\u2019s neuroinflammation: A crosstalk between immune checkpoint PD1-PDL1 and ApoE-Heparin interactions? Med Hypotheses 164:110865","journal-title":"Med Hypotheses"},{"issue":"38","key":"10206_CR103","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N et al (2020) Revisiting the PD-1 pathway. Sci Adv 6(38):eabd2712","journal-title":"Sci Adv"},{"key":"10206_CR104","unstructured":"Piancone F (2013) Immune mechanisms associated to neuroinflammation in Alzheimer\u2019s. Disease"},{"key":"10206_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-0978-3","volume":"14","author":"CK Prajeeth","year":"2017","unstructured":"Prajeeth CK et al (2017) Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties. J Neuroinflammation 14:1\u201314","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10206_CR106","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","volume":"12","author":"S Rakshit","year":"2020","unstructured":"Rakshit S, Molina JR (2020) Immunotherapy in patients with autoimmune disease. J Thorac Dis 12(11):7032","journal-title":"J Thorac Dis"},{"key":"10206_CR107","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fcimb.2019.00436","volume":"9","author":"VR Reddy","year":"2019","unstructured":"Reddy VR et al (2019) In vitro interactions of chicken programmed cell death 1 (PD-1) and PD-1 ligand-1 (PD-L1). Front Cell Infect Microbiol 9:436","journal-title":"Front Cell Infect Microbiol"},{"key":"10206_CR108","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2516.2006.01363.x","volume":"12","author":"M Reding","year":"2006","unstructured":"Reding M (2006) Immunological aspects of inhibitor development. Haemophilia 12:30\u201336","journal-title":"Haemophilia"},{"issue":"10","key":"10206_CR109","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1055\/s-0037-1613257","volume":"88","author":"MT Reding","year":"2002","unstructured":"Reding MT et al (2002) Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 88(10):568\u2013575","journal-title":"Thromb Haemost"},{"issue":"11","key":"10206_CR110","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos M, Scharping NE, Goldrath AW (2021) CD8+ T cell metabolism in infection and cancer. Nat Rev Immunol 21(11):718\u2013738","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10206_CR111","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds KL, Guidon AC (2019) Diagnosis and management of immune checkpoint Inhibitor-Associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24(4):435\u2013443","journal-title":"Oncologist"},{"issue":"1","key":"10206_CR112","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/01.wnl.0000438216.93319.ab","volume":"82","author":"G Ristori","year":"2014","unstructured":"Ristori G et al (2014) Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 82(1):41\u201348","journal-title":"Neurology"},{"issue":"1","key":"10206_CR113","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41467-019-08352-5","volume":"10","author":"N Rosenzweig","year":"2019","unstructured":"Rosenzweig N et al (2019) PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun 10(1):465","journal-title":"Nat Commun"},{"issue":"1","key":"10206_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-024-03255-9","volume":"21","author":"W Rui","year":"2024","unstructured":"Rui W et al (2024) Myeloid gasdermin D drives early-stage T cell immunity and peripheral inflammation in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation 21(1):1\u201323","journal-title":"J Neuroinflammation"},{"key":"10206_CR115","doi-asserted-by":"publisher","first-page":"641428","DOI":"10.3389\/fonc.2021.641428","volume":"11","author":"BL Russell","year":"2021","unstructured":"Russell BL et al (2021) The tumor microenvironment factors that promote resistance to immune checkpoint blockade therapy. Front Oncol 11:641428","journal-title":"Front Oncol"},{"issue":"10","key":"10206_CR116","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A et al (2019) PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol 234(10):16824\u201316837","journal-title":"J Cell Physiol"},{"key":"10206_CR117","doi-asserted-by":"crossref","unstructured":"Salminen A (2024)\u00a0The role of inhibitory immune checkpoint receptors in the pathogenesis of Alzheimer\u2019s disease. J Mol Med 1\u201319","DOI":"10.1007\/s00109-024-02504-x"},{"issue":"6","key":"10206_CR118","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00109-024-02444-6","volume":"102","author":"A Salminen","year":"2024","unstructured":"Salminen A (2024b) The role of the immunosuppressive PD-1\/PD-L1 checkpoint pathway in the aging process and age-related diseases. J Mol Med 102(6):733\u2013750","journal-title":"J Mol Med"},{"issue":"3","key":"10206_CR119","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.neurobiolaging.2011.03.004","volume":"33","author":"M Saresella","year":"2012","unstructured":"Saresella M et al (2012) (2012) A potential role for the PD1\/PD-L1 pathway in the neuroinflammation of Alzheimer\u2019s disease. Neurobiol Aging 33(3):624","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10206_CR120","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jns.12605","volume":"29","author":"A Sarkar","year":"2024","unstructured":"Sarkar A et al (2024) Synergistic effects of immune checkpoints and checkpoint inhibitors in inflammatory neuropathies: Implications and mechanisms. J Peripher Nerv Syst 29(1):6\u201316","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"10206_CR121","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1172\/JCI90606","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus H, Heneka MT (2017) Microglia in Alzheimer\u2019s disease. J Clin Investig 127(9):3240\u20133249","journal-title":"J Clin Investig"},{"key":"10206_CR122","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3389\/fimmu.2017.01905","volume":"8","author":"ST Schetters","year":"2018","unstructured":"Schetters ST et al (2018) Neuroinflammation: microglia and T cells get ready to tango. Front Immunol 8:1905","journal-title":"Front Immunol"},{"issue":"10","key":"10206_CR123","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/eji.200838137","volume":"38","author":"B Schreiner","year":"2008","unstructured":"Schreiner B et al (2008) PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol 38(10):2706\u20132717","journal-title":"Eur J Immunol"},{"issue":"12","key":"10206_CR124","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/jcm8122168","volume":"8","author":"B Seliger","year":"2019","unstructured":"Seliger B (2019) Basis of PD1\/PD-L1 therapies. J Clin Med 8(12):2168","journal-title":"J Clin Med"},{"issue":"3","key":"10206_CR125","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jcbfm.2009.240","volume":"30","author":"BD Semple","year":"2010","unstructured":"Semple BD, Kossmann T, Morganti-Kossmann MC (2010) Role of chemokines in CNS health and pathology: a focus on the CCL2\/CCR2 and CXCL8\/CXCR2 networks. J Cereb Blood Flow Metab 30(3):459\u2013473","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10206_CR126","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cns.13760","volume":"28","author":"Y Shen","year":"2022","unstructured":"Shen Y et al (2022) The immunomodulatory effect of microglia on ECM neuroinflammation via the PD-1\/PD-L1 pathway. CNS Neurosci Ther 28(1):46\u201363","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"10206_CR127","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3070","volume":"11","author":"C Shi","year":"2011","unstructured":"Shi C, Pamer EG (2011) Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11(11):762\u2013774","journal-title":"Nat Rev Immunol"},{"key":"10206_CR128","doi-asserted-by":"publisher","first-page":"932152","DOI":"10.3389\/fimmu.2022.932152","volume":"13","author":"Y Shi","year":"2022","unstructured":"Shi Y et al (2022) Th17 cells and inflammation in neurological disorders: Possible mechanisms of action. Front Immunol 13:932152","journal-title":"Front Immunol"},{"issue":"4","key":"10206_CR129","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrn785","volume":"3","author":"SS Sisodia","year":"2022","unstructured":"Sisodia SS, St George-Hyslop PH (2022) \u03b3-Secretase, Notch, A\u03b2 and Alzheimer\u2019s disease: where do the presenilins fit in? Nat Rev Neurosci 3(4):281\u2013290","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10206_CR130","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","volume":"87","author":"JA Smith","year":"2012","unstructured":"Smith JA et al (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87(1):10\u201320","journal-title":"Brain Res Bull"},{"issue":"1","key":"10206_CR131","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-023-02917-4","volume":"20","author":"BC Smith","year":"2023","unstructured":"Smith BC et al (2023) Astrocyte interferon-gamma signaling dampens inflammation during chronic central nervous system autoimmunity via PD-L1. J Neuroinflammation 20(1):234","journal-title":"J Neuroinflammation"},{"key":"10206_CR132","doi-asserted-by":"crossref","unstructured":"Smolders J et al (2022) T-cell surveillance of the human brain in health and multiple sclerosis. In Seminars in immunopathology. Springer","DOI":"10.1007\/s00281-022-00926-8"},{"key":"10206_CR133","doi-asserted-by":"publisher","first-page":"566225","DOI":"10.3389\/fimmu.2020.566225","volume":"11","author":"Z Stoji\u0107-Vukani\u0107","year":"2020","unstructured":"Stoji\u0107-Vukani\u0107 Z et al (2020) CD8+ T Cell-mediated mechanisms contribute to the progression of neurocognitive impairment in both multiple sclerosis and Alzheimer\u2019s disease? Front Immunol 11:566225","journal-title":"Front Immunol"},{"issue":"3","key":"10206_CR134","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0301-0082(98)00083-5","volume":"58","author":"G Stollg","year":"1999","unstructured":"Stollg G, Jander S (1999) The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 58(3):233\u2013247","journal-title":"Prog Neurobiol"},{"key":"10206_CR135","doi-asserted-by":"crossref","unstructured":"Subhramanyam CS et al (2019) Microglia-mediated neuroinflammation in neurodegenerative diseases. In Seminars in cell & developmental biology. Elsevier","DOI":"10.1016\/j.semcdb.2019.05.004"},{"issue":"1","key":"10206_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S et al (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46(1):1\u201317","journal-title":"Inflammation"},{"key":"10206_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23:1\u201311","journal-title":"AAPS J"},{"issue":"1","key":"10206_CR138","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1570159X19666210826130210","volume":"20","author":"MS Uddin","year":"2022","unstructured":"Uddin MS et al (2022) Neuroinflammatory signaling in the pathogenesis of Alzheimer\u2019s disease. Curr Neuropharmacol 20(1):126\u2013146","journal-title":"Curr Neuropharmacol"},{"key":"10206_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02407-8","volume":"22","author":"S Vafaei","year":"2022","unstructured":"Vafaei S et al (2022) Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 22:1\u201327","journal-title":"Cancer Cell Int"},{"key":"10206_CR140","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A et al (2020) The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol 11:1951","journal-title":"Front Immunol"},{"issue":"3","key":"10206_CR141","first-page":"276","volume":"10","author":"A Vakilian","year":"2019","unstructured":"Vakilian A et al (2019) Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer\u2019s disease. Caspian J Intern Med 10(3):276","journal-title":"Caspian J Intern Med"},{"key":"10206_CR142","doi-asserted-by":"publisher","first-page":"642800","DOI":"10.3389\/fneur.2021.642800","volume":"12","author":"C Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez C, Zekeridou A (2021) Paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy. Front Neurol 12:642800","journal-title":"Front Neurol"},{"issue":"2","key":"10206_CR143","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.trci.2016.05.001","volume":"2","author":"LJ Van Eldik","year":"2016","unstructured":"Van Eldik LJ et al (2016) The roles of inflammation and immune mechanisms in Alzheimer\u2019s disease. Alzheimer\u2019s Dement: Transl Res Clin Interv 2(2):99\u2013109","journal-title":"Alzheimer's Dement: Transl Res Clin Interv"},{"issue":"9","key":"10206_CR144","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","volume":"6","author":"R Vassar","year":"2014","unstructured":"Vassar R (2014) BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy 6(9):89","journal-title":"Alzheimer's Res Therapy"},{"issue":"41","key":"10206_CR145","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar R et al (2009) The \u03b2-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29(41):12787\u201312794","journal-title":"J Neurosci"},{"issue":"751","key":"10206_CR146","doi-asserted-by":"publisher","first-page":"eadj9672","DOI":"10.1126\/scitranslmed.adj9672","volume":"16","author":"JM Vinnakota","year":"2024","unstructured":"Vinnakota JM et al (2024) Anti\u2013PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation. Sci Transl Med 16(751):eadj9672","journal-title":"Sci Transl Med"},{"key":"10206_CR147","unstructured":"Voice MA (2015) The biology of CD4+ T cells in the blood and central nervous system. University of Birmingham"},{"key":"10206_CR148","doi-asserted-by":"crossref","unstructured":"Vos Q et al (2000) B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176(1)","DOI":"10.1034\/j.1600-065X.2000.00607.x"},{"issue":"3","key":"10206_CR149","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cei.12858","volume":"186","author":"A Vultaggio","year":"2016","unstructured":"Vultaggio A et al (2016) Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin Exp Immunol 186(3):364\u2013372","journal-title":"Clin Exp Immunol"},{"issue":"20","key":"10206_CR150","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","volume":"20","author":"DA Wainwright","year":"2014","unstructured":"Wainwright DA et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20(20):5290\u20135301","journal-title":"Clin Cancer Res"},{"key":"10206_CR151","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10875-008-9251-y","volume":"28","author":"YY Wan","year":"2008","unstructured":"Wan YY, Flavell RA (2008) TGF-\u03b2 and regulatory T cell in immunity and autoimmunity. J Clin Immunol 28:647\u2013659","journal-title":"J Clin Immunol"},{"issue":"10","key":"10206_CR152","first-page":"136","volume":"3","author":"WY Wang","year":"2015","unstructured":"Wang WY et al (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease. Ann Transl Med 3(10):136","journal-title":"Ann Transl Med"},{"key":"10206_CR153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-1018-6","volume":"38","author":"X Wang","year":"2019","unstructured":"Wang X et al (2019) Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res 38:1\u201313","journal-title":"J Exp Clin Cancer Res"},{"key":"10206_CR154","doi-asserted-by":"publisher","first-page":"670391","DOI":"10.3389\/fimmu.2021.670391","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M et al (2021) The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front Immunol 12:670391","journal-title":"Front Immunol"},{"key":"10206_CR155","doi-asserted-by":"crossref","unstructured":"Wang X et al (2016) PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy 5023\u20135039","DOI":"10.2147\/OTT.S105862"},{"key":"10206_CR156","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12013-013-9763-9","volume":"69","author":"W Wu","year":"2014","unstructured":"Wu W et al (2014) Human amnion mesenchymal cells negative co-stimulatory molecules PD-L1 expression and its capacity of modulating microglial activation of CNS. Cell Biochem Biophys 69:35\u201345","journal-title":"Cell Biochem Biophys"},{"issue":"1","key":"10206_CR157","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13578-022-00897-1","volume":"12","author":"C-T Wu","year":"2022","unstructured":"Wu C-T et al (2022) A change of PD-1\/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer\u2019s disease. Cell Biosci 12(1):162","journal-title":"Cell Biosci"},{"key":"10206_CR158","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bbi.2020.09.015","volume":"91","author":"Z Xing","year":"2021","unstructured":"Xing Z et al (2021) Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-\u03b2 accumulation and improves cognition in APP\/PS1 mice. Brain Behav Immun 91:128\u2013141","journal-title":"Brain Behav Immun"},{"key":"10206_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0455-6","volume":"10","author":"S Xue","year":"2017","unstructured":"Xue S et al (2017) Blocking the PD-1\/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol 10:1\u201310","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10206_CR160","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000495465","volume":"26","author":"Y Yang","year":"2019","unstructured":"Yang Y et al (2019) Acute traumatic brain injury induces CD4+ and CD8+ T cell functional impairment by upregulating the expression of PD-1 via the activated sympathetic nervous system. NeuroImmunoModulation 26(1):43\u201357","journal-title":"NeuroImmunoModulation"},{"issue":"2","key":"10206_CR161","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/21645515.2020.1782692","volume":"17","author":"T Yang","year":"2021","unstructured":"Yang T, Kong Z, Ma W (2021) PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential. Hum Vaccin Immunother 17(2):546\u2013553","journal-title":"Hum Vaccin Immunother"},{"issue":"18","key":"10206_CR162","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.7150\/thno.75965","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang H et al (2022) Adoptive therapy with amyloid-\u03b2 specific regulatory T cells alleviates Alzheimer\u2019s disease. Theranostics 12(18):7668","journal-title":"Theranostics"},{"issue":"4","key":"10206_CR163","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/PPO.0000000000000060","volume":"20","author":"S Yao","year":"2014","unstructured":"Yao S, Chen L (2014) PD-1 as an immune modulatory receptor. Cancer J 20(4):262\u2013264","journal-title":"Cancer J"},{"issue":"12","key":"10206_CR164","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","volume":"13","author":"LM Yshii","year":"2017","unstructured":"Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13(12):755\u2013763","journal-title":"Nat Rev Neurol"},{"key":"10206_CR165","doi-asserted-by":"crossref","unstructured":"Zeng J et al (2024) T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease. Neurobiol Dis 106461","DOI":"10.1016\/j.nbd.2024.106461"},{"issue":"3","key":"10206_CR166","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang X et al (2004) Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20(3):337\u2013347","journal-title":"Immunity"},{"key":"10206_CR167","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fncel.2014.00271","volume":"8","author":"S Zhao","year":"2014","unstructured":"Zhao S et al (2014) Regulation of neuroinflammation through programed death-1\/programed death ligand signaling in neurological disorders. Front Cell Neurosci 8:271","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"10206_CR168","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s12264-021-00683-y","volume":"37","author":"J Zhao","year":"2021","unstructured":"Zhao J et al (2021) Emerging role of PD-1 in the central nervous system and brain diseases. Neurosci Bull 37(8):1188\u20131202","journal-title":"Neurosci Bull"},{"issue":"17","key":"10206_CR169","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/j.neuron.2023.05.022","volume":"111","author":"J Zhao","year":"2023","unstructured":"Zhao J et al (2023) PD-L1\/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior. Neuron 111(17):2709-2726. e9","journal-title":"Neuron"},{"key":"10206_CR170","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225","journal-title":"Eur J Cancer"},{"key":"10206_CR171","doi-asserted-by":"publisher","first-page":"769229","DOI":"10.3389\/fcell.2021.769229","volume":"9","author":"Y Zou","year":"2021","unstructured":"Zou Y et al (2021) Programmed cell death protein 1 blockade reduces glycogen synthase kinase 3\u03b2 activity and tau hyperphosphorylation in Alzheimer\u2019s disease mouse models. Front Cell Dev Biol 9:769229","journal-title":"Front Cell Dev Biol"},{"key":"10206_CR172","doi-asserted-by":"crossref","unstructured":"Zschaler J, Schlorke D, Arnhold J (2014) Differences in innate immune response between man and mouse. Crit Rev \u2122 Immunol 34(5)","DOI":"10.1615\/CritRevImmunol.2014011600"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-025-10206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-025-10206-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-025-10206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T11:03:48Z","timestamp":1745665428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-025-10206-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":172,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10206"],"URL":"https:\/\/doi.org\/10.1007\/s11481-025-10206-5","relation":{},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"46"}}